Current treatments for renal failure due to multiple myeloma

References

• Hutchison CA, Bladé J, Cockwell P, et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012;8(4):234–243.
   PubMed Web of Science ®Google Scholar
• Leung N, Nasr SH. Myeloma-related kidney disease. Adv Chronic Kidney Dis. 2014;21(1):36–47.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2013;14(11):1477–1495.
   PubMed Web of Science ®Google Scholar
• Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25(2):419–426.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200.
   PubMed Web of Science ®Google Scholar
• Uttervall K, Duru AD, Lund J, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One. 2014;9(7):e101819.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwel LP, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–1136.
   PubMed Web of Science ®Google Scholar
• Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786–794.
   PubMed Web of Science ®Google Scholar
• Basnayake K, Stringer SJ, Hutchison CA, et al. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79(12):1289–1301.
   PubMed Web of Science ®Google Scholar
• Ying W-Z, Wang P-X, Aaron KJ, et al. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood. 2011;117(4):1301–1307.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011;8(1):43–51.
   PubMed Web of Science ®Google Scholar
• Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012;7(12):1964–1968.
   PubMed Web of Science ®Google Scholar
• Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–239.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266.
   PubMed Web of Science ®Google Scholar
• Tosi P, Tomassetti S, Merli A, et al. Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Ther Adv Hematol. 2013;4(1):37–41.
   PubMedGoogle Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976–4984.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmi DCH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kastritis E, et al. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations? Eur J Haematol. 2013;91(4):347–355.
   PubMed Web of Science ®Google Scholar
• Papassotiriou GP, Kastritis E, Gkotzamanidou M, et al. Neutrophil gelatinase-associated lipocalin and cystatin C are sensitive markers of renal injury in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(1):29–35.
   PubMed Web of Science ®Google Scholar
• Ando M, Mori J, Ohashi K, et al. A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplant. 2010;45(9):1427–1434.
   PubMed Web of Science ®Google Scholar
• Shi H, Zhang W, Li X, et al. Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: a 15-year retrospective, single center, cohort study. Leuk Lymphoma. 2014;55(5):1076–1082.
   PubMed Web of Science ®Google Scholar
• Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma. 2011;52(12):2299–2303.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188.
   PubMed Web of Science ®Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–2357.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635–4641.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423–429.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499–502.
   PubMed Web of Science ®Google Scholar
• Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA registry study. Nephrol Dial Transplant. 2010;25(4):1200–1206.
   PubMed Web of Science ®Google Scholar
• Decourt A, Gondouin B, Delaroziere JC, et al. Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis. Clin J Am Soc Nephrol. 2016;11(3):431–441.
   PubMed Web of Science ®Google Scholar
• Cobb J, Plantinga L, Luthi J-C, et al. Pre-ESRD care and mortality in incident ESRD patients with multiple myeloma. Am J Clin Oncol. 2016; doi:10.1097/COC.0000000000000275. [Epub ahead of print]
   PubMedGoogle Scholar
• Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. Br Med J (Clin Res Ed). 1984;288(6428):1411–1416.
   PubMedGoogle Scholar
• Cohen B, Laish I, Brosh-Nissimov T, et al. Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial. Am J Emerg Med. 2013;31(12):1703–1706.
   PubMed Web of Science ®Google Scholar
• Matsue K, Fujiwara H, Iwama K, et al. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol. 2010;89(3):291–297.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546–549.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990;150(8):1693–1695.
   PubMedGoogle Scholar
• Ramasamy K, Dimopoulos MA, Niels W, et al. Safety of treatment (Tx) with pomalidomide (POM) and low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) and renal impairment (RI), including those on dialysis. Blood Abstact 374, ASH, Annual Meeting; 2015 Dec 6; Orlando (FL).
   Google Scholar
• Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364(24):2365–2366.
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84(3):223–228.
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Mazzone C, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118(22):5759–5766.
   PubMed Web of Science ®Google Scholar
• Scheid C, Sonneveld P, Schmidt-Wolf IG, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–154.
   PubMed Web of Science ®Google Scholar
• Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122(1):160–161.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol. 2004;125(1):96–97.
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Tacchetti P, et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant. 2010;16(8):1115–1121.
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73(2):98–103.
   PubMed Web of Science ®Google Scholar
• Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90(4):429–439.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116(16):3807–3814.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Rauch E, Kuehr T, et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2015;100(3):385–391.
   PubMed Web of Science ®Google Scholar
• De La Rubia J, Roig M, Ibáñez A, et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol. 2010;85(4):363–365.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71(2):489–501.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Vij R, Richardson P, Siegel DS, et al. Pomalidomide plus low-dose dexamethasone (POM+LoDEX) in RRMM: analyses based on prior therapy and renal function. Clin Lymphoma Myeloma Leuk (IMW Annu Meet Abstr). 2013;13 (Suppl. 1). Abstract S14-1.
   Google Scholar
• Siegel DS, Richardson P, Baz R, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): impact of renal function on patient outcomes. Blood (ASH Annu Meet Abstr). 2012;Abstract 120.
   Google Scholar
• Weisel KC,, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM+LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol (ASCO Annu Meet Proc). 2013;31(Suppl). Abstract 8527.
   Google Scholar
• Weisel K, Dimopoulos MA, Cavo M, et al. Pomalidomide + low-dose dexamethasone in patients with refractory or relapsed multiple myeloma and renal impairment: analysis of aptients from the phse 3b stratus trial (MM-010). Blood. 2014;124:Abst 4755.
   Google Scholar
• Matous J, Siegel DS, Lonial S, et al. MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of Pomalidomide + low-dose dexamethasone in patients with relapsed or refractory and refractory multiple and renal impairment. Blood (Meeting Abstracts). 2014;124:Abstr 4730.
   Google Scholar
• Sonneveld P, Heyne N, Kueenburg E, et al. MM-013: an ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis. J Clin Oncol. 2014;32:52; suppl; abstr TPS8626.
   Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Siegel D, et al. Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. Ann Oncol. 2015;26(11):2247–2256.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573–1585.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 2016;96(6);564–577. doi:10.1111/ejh.12749. Epub 2016 Mar 9.
   Web of Science ®Google Scholar
• Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27(8):1707–1714.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–2825.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–1761.
   PubMed Web of Science ®Google Scholar
• Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87–96.
   PubMedGoogle Scholar
• Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos MA, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jannagath S, Zonder J, et al. Pharmacokinetics and safety of Elotuzumab combined with Lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a Phase Ib Study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–138.
   PubMed Web of Science ®Google Scholar
• Yan X, Clemens P, Puchalski T, et al., Target-mediated drug disposition of Daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. ASH Oral and Poster Abstracts (Annual Meeting); 2015 Dec 6; Orlando (FL).
   Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1556.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40(5):634–651.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). ASH Abstracts (Annual Meeting); 2015 Dec 6; Orlando (FL).
   Google Scholar
• Gupta N, Hanley MJ, Harvey DR, et al. Phase 1/1b pharmacokinetic (PK) and safety study of the investigational oral proteasome inhibitor (PI) ixazomib in relapsed/refractory multiple myeloma (RRMM) patients (Pts) with severe renal impairment or end-stage renal disease (ESRD) requiring hemodialysis. ASH Annual Meeting Abstract; 2015 Dec 6; Orlando (FL).
   Google Scholar
• Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2(6):947–952.
   PubMed Web of Science ®Google Scholar
• Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35(10):985–990.
   PubMed Web of Science ®Google Scholar
• El Fakih R, Fox P, Popat U, et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk. 2015;15(8):472–476.
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–829.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1(1):28–36.
   PubMedGoogle Scholar
• Knudsen LM, Nielsen B, Gimsing P, et al. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75(1):27–33.
   PubMed Web of Science ®Google Scholar
• Glavey SV, Gertz MA, Dispenzieri A, et al. Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant. 2013;48(12):1543–1547.
   PubMed Web of Science ®Google Scholar
• St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50(1):95–99.
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Heiss C, Perne A, et al. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant. 2014;49(11):1371–1375.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27(10):3823–3828.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4(4):745–754.
   PubMed Web of Science ®Google Scholar
• Harding S, Provot F, Beuscart JB, et al. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant. 2011;26(4):1438.
   PubMed Web of Science ®Google Scholar
• Zannetti BA, Zamagni E, Santostefano M, et al. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 2015;90(7):647–652.
   PubMed Web of Science ®Google Scholar
• Nayak L, Lazarus HM. Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion? Bone Marrow Transplant. 2013;48(3):338–345.
   PubMed Web of Science ®Google Scholar